CD8A and neoplasm: By contrast, mice treated with the C‐PC, and to a greater extent the C‐P, CDK4/6i priming regimens displayed higher CD4+ and CD8+ T cell abundance versus either monotherapy and other treatment groups in all three tumor models (Figure 3b).